BioCentury
ARTICLE | Emerging Company Profile

CatalYm: opening up tumors to immune cells

Emerging Company Profile: German start-up targets GDF15’s immunosuppressant function to enable immune cell infiltration to tumors

November 11, 2020 12:15 AM UTC

CatalYm is targeting a lesser known immunosuppressant function of GDF15 to resensitize cancer patients to checkpoint blockade and enhance the ability of CAR T therapies to infiltrate solid tumors.

The Munich-based biotech has raised €50 million ($58.2 million) in a series B round led by Vesalius Biocapital III to bring lead program CTL-002 into a large Phase I trial to treat multiple solid tumors...

BCIQ Company Profiles

CatalYm GmbH